

# MPH Health Care AG

Germany / Healthcare  
 Frankfurt  
 Bloomberg: 93M1 GR  
 ISIN: DE000A289V03

H1 results

## RATING

### PRICE TARGET

Return Potential  
 Risk Rating

## BUY

€ 108.00

353.8%  
 High

## NAV ECLIPSES €300M THRESHOLD

As expected, MPH reported sizable NAV uplift with six month reporting. NAV was up some 30% at the end of the June period and 58% Y/Y to €326m, while NAVPS moved in lockstep landing at €76. M1 Kliniken shares were up 63% at the end of June spurred by publication of a bullish mid-term outlook, and now the beauty specialist is drawing significant private equity interest. Meanwhile, the other core holding, CR Energy, reported a solid set of 2023 results, but shares were down around 8% at the 6M juncture. M1 is continuing its march towards 150 to 200 clinics by YE29, and CRE's clean energy and quality, affordable housing businesses continue to flourish. Our SotP model factors in the updated stakes in M1 and CRE and points to a €108 TP (old: €113). We stick to our Buy rating.

**M1's injectables business is on a heater.** . . . H1 reporting once again showcased the growing strength of M1's injectables business. Beauty segment sales were up some 31% to €48.6m in the six months to end June and EBIT overshoot FBe by a wide margin (overleaf). Segment EBIT was up 24% to €10.1m (H1/23: €8.1m), and the margin topped the targeted 20% threshold at 20.8% (H1/23: 21.8%). Trade segment revenue eclipsed €119m and beat the prior year comp by 5%, while segment EBIT was back in the black at €4.4m vs minus €0.8m last year, when one-off eliminations burdened the KPI.

**. . . and private equity wants in on the action** Meanwhile, M1 shares caught a sizable bid recently when management gave a brief update on previously communicated private equity (PE) interest in M1's Beauty business, noting that six well-known PE outfits have expressed interest in "investing in or acquiring the Beauty segment." The med spa economy is thriving, and the researcher, Market.us, reckons the market was worth some \$17bn in 2023, while beauty-obsessed folk were thought to have shelled out close to \$10bn for fresher facial appearances last year. M1 brass first said in February that. . . (p.t.o.)

## FINANCIAL HISTORY & PROJECTIONS

	2020	2021	2022	2023	2024E	2025E
Operating rev. (€m)	3.4	13.5	30.7	34.5	81.0	42.7
Y/Y growth	-91.7%	294.6%	126.4%	12.4%	135.2%	-47.3%
EBIT (€m)	-71.0	-9.1	29.6	30.2	78.3	39.9
Pre-tax income (€m)	-71.5	-9.2	29.5	29.8	78.0	39.6
Net income (€m)	-70.4	-9.0	29.1	29.5	76.4	38.8
EPS (diluted) (€)	-16.44	-2.09	6.80	6.90	17.85	9.07
DPS (€)	0.00	0.00	0.00	1.20	1.20	1.20
NAV (€m)	201.3	192.3	221.4	251.0	322.2	355.9
NAVPS (€)	47.0%	44.9%	51.7%	58.6%	75.3%	83.1%
Liquid assets (€m)	4.2	4.4	3.8	5.1	5.5	12.1

## RISKS

Regulatory changes in healthcare systems, homogenization of pharmaceutical prices within the EU, and prolonged macro economic downturns that limit private healthcare spend.

## COMPANY PROFILE

MPH Health Care AG is a Berlin-based investment company focused on the purchase and further development of companies positioned chiefly in growth segments of the healthcare market. These primarily entail specialty pharmaceuticals for chronic diseases and lifestyle and beauty treatments. The company also holds a stake in a residential property developer.

## MARKET DATA

As of 07 Oct 2024

Closing Price	€ 23.80
Shares outstanding	4.28m
Market Capitalisation	€ 101.89m
52-week Range	€ 13.65 / 34.60
Avg. Volume (12 Months)	3,211

Multiples	2023	2024E	2025E
P/E	3.4	1.3	2.6
EV/Sales	3.6	1.4	2.7
P/NAV	0.5	0.5	0.4
Div. Yield	5.0%	5.0%	5.0%

## STOCK OVERVIEW



## COMPANY DATA

As of 30 Jun 2024

Liquid Assets	€ 7.30m
Current Assets	€ 9.10m
Financial Assets	€ 334.50m
Total Assets	€ 343.70m
Current Liabilities	€ 6.80m
Shareholders' Equity	€ 325.50m

## SHAREHOLDERS

Magnum	60.0%
Baring Fund Managers	1.7%
KBC Asset Management SA	1.3%
Free Float	37.0%



. . . the lifestyle and beauty specialist was drawing PE interest. This comes as no surprise. M1's Beauty business offers a wealth of expansion opportunities across numerous markets, including America, making it an attractive takeover target. After a run of quarters with segment EBIT margins topping 20%, the earnings potential is now clearly visible

**If the price is right** It remains to be seen whether M1 brass want to play the long game, but everything has its price. Management hinted at a 30x EBITDA multiple in February, and private equity is known for its deep pockets. We would not be surprised if one of the mentioned six suitors wrote a cheque to buy in or acquire the Beauty business outright. If not, we think the company has all the pieces in place to hit its growth targets.

**Table 1: M1 Kliniken Q2 results vs FBe and prior year**

EURm	Q2/24	Q2/24E	Variance	Q2/23	Variance	6M/24	6M/23	Variance
Revenue	83.0	81.8	1%	74.0	12%	167.7	150.8	11%
Beauty	23.9	20.5	17%	16.3	47%	48.6	37.2	31%
Trade	59.1	61.3	-4%	57.7	2%	119.1	113.6	5%
EBITDA	8.2	6.5	26%	4.6	78%	17.0	9.9	71%
Margin	9.9%	7.9%	-	6.2%	-	10.1%	6.6%	-
EBIT	7.7	5.7	35%	3.3	133%	14.5	7.3	99%
Margin	9.3%	7.0%	-	4.5%	-	8.6%	4.8%	-

Source: First Berlin Equity Research; M1 Kliniken AG

**Full steam ahead at CR Energy** The investment holding is expected to publish half year 2024 results in the coming weeks. Audited 2023 reporting showed another good performance during a headwind year for the property sector. EBITDA tallied €66m vs €76m in 2022 (FBe: €76m). The Y/Y decline stems from lower portfolio revaluation gains booked in 2023 than the prior year. Operating cash flow (CFO) climbed 42% Y/Y to €23.5 allowing CRE to exit the year flush with cash (€19.5m) to deploy for growing operations. Meanwhile, the 27 June AGM nodded through the issuance of bonus shares in lieu of a cash dividend payout, and each share became four.

**Table 2: CR Energy 2023 results vs FBe and prior year**

All figures in EUR '000	2023	2023E	Variance	2022	Variance
Investment revenue	68,644	76,136	-9.8%	79,407	-13.6%
EBITDA	66,429	74,460	-10.8%	76,302	-12.9%
Margin (%)	97%	98%	-	96%	-
Net income	66,308	73,309	-9.5%	75,305	-11.9%
EPS diluted (€)	11.7	12.9	-9.5%	18.1	-35.4%

Source: First Berlin Equity Research; CR Energy AG

CR Opportunities will launch a European Long Term Investment Fund (ELTIF) of ~€100m this summer and populate it with properties in need of refurbishment, which will play off the synergies with CRE's Terrabau and Solartec holdings. The overall business surge is part of CRE's recently unveiled 2027 strategy that aims for AuM (assets under management) of €1bn at CRO in 5 years.



## MPH 2023 SIX MONTH REPORTING

MPH reported NAV of €326m at the end of June (+58% YY), and NAVPS rose in lockstep to €76. The uplift owes to the €75m net profit traced to €84m in non-cash fair value write-ups. There was no investment income, since dividend and profit distributions normally impact H2 results.

**Table 3: Six month results vs FBe and prior year**


All figures in EUR '000	6M/24	6M/24E	variance	6M/23	variance
Operating revenue	84,169	21,450	292%	355	n.m.
Operating income	75,741	19,883	281%	-15,594	-
Net income	74,524	19,520	282%	-15,407	-
NAVPS (€)	76.0	63.2	20%	58.6	30%

Source: First Berlin Equity Research; MPH Health Care AG

Revaluation gains were mainly spurred by the 63% rally in M1 shares during H1, the impact of which was lessened by an 8% slide in the CR Energy stock price. MPH also trimmed its M1 position to 61% (YE23: 65%) and its stake in CRE to 56% (YE23: 57%) in the January-to-June period.

M1 beat Q2 expectations (table 1) by a wide margin to kick off 2024, while CR Energy is expected to publish six month results in the coming weeks. We think these will show continued good business momentum after racking up some €66m in net income last year.

**Figure 1: MPH NAV and NAVPS developments**



Source: First Berlin Equity Research; MPH Health Care AG

**Table 4: 6M financial highlights**

All figures in EUR '000	6M/24	2023	variance
Cash & liquid assets	7,332	5,094	44%
Financial assets	334,549	259,249	29%
Financial debt (short- and long-term)	14,965	13,047	15%
Net debt / (cash)	7,633	7,953	-4%
Total assets	343,668	266,352	29%
Shareholders' equity	325,490	250,966	30%
Equity ratio	95%	94%	-
NAV	325,490	250,966	30%
NAVPS (€)	76.0	58.6	30%

Source: First Berlin Equity Research; MPH Health Care AG

## VALUATION MODEL

**We maintain our Buy rating on MPH** Our price target for MPH dips to €108 (old: €113) after factoring the adjusted stakes in M1 and CRE into our sum-of-the-parts model. We still see fair value for M1 at €28 per share. Our CR Energy TP is now €12 (old: €48) after adjusting for the company's recent stock split, i.e. bonus share issuance.

**Table 5: MPH Sum-of-the-parts and changes to prior update**

Unit	Shareholdings '000	SO '000	MPH stake %	Share price* €	Fair value per share <sup>1</sup> €	Projected value €m
M1 Kliniken AG	11,975	19,643	61%	15.7	28.0	335
CR Energy AG	12,728	23,520	54%	6.0	12.0	153
<b>Projected value of listed holdings</b>						<b>488</b>

\* Source: Bloomberg (Previous day's closing price)

	Unit	Value
Fair value of listed portfolio	€m	488
Non-listed investment (book value)	€m	25
Net debt / (cash) (2022)	€m	8
Present value of holding costs	€m	42
<b>Total fair value</b>	<b>€m</b>	<b>463</b>
MPH shares outstanding	m	4
<b>Fair value per share</b>	<b>€</b>	<b>108</b>

<sup>1</sup> First Berlin Equity Research covers CR Energy (Buy / PT: EUR 2); M1 (Buy / PT: EUR 28); CRE KPIs reflect new share count after the stock split

	Unit	New	Old	Variance
Fair value of listed portfolio	€m	488	509	-4%
Non-listed investment (book value)	€m	25	25	0%
Net debt	€m	8	8	-1%
Present value of holding costs	€m	42	41	3%
<b>Total fair value</b>	<b>€m</b>	<b>463</b>	<b>484</b>	<b>-4%</b>
MPH shares outstanding	m	4	4	0%
<b>Fair value per share</b>	<b>€</b>	<b>108</b>	<b>113</b>	<b>-4%</b>



Table 6: M1 Kliniken DCF model

	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E
<b>Sales</b>	<b>333,149</b>	<b>371,733</b>	<b>414,840</b>	<b>456,421</b>	<b>497,125</b>	<b>533,766</b>	<b>565,490</b>	<b>591,996</b>
<b>NOPLAT</b>	<b>14,808</b>	<b>18,659</b>	<b>22,839</b>	<b>28,976</b>	<b>34,760</b>	<b>41,213</b>	<b>47,286</b>	<b>52,869</b>
(+) depreciation & amortisation	5,028	5,467	5,601	5,978	6,212	6,483	6,562	6,718
<b>(=) Net operating cash flow</b>	<b>19,836</b>	<b>24,126</b>	<b>28,440</b>	<b>34,954</b>	<b>40,972</b>	<b>47,696</b>	<b>53,848</b>	<b>59,587</b>
(-) Total investments (CapEx and WC)	-3,731	-9,544	-10,203	-10,448	-10,634	-10,454	-10,098	-9,691
(-) Capital expenditures	-4,918	-5,431	-5,638	-6,090	-6,391	-6,721	-6,842	-7,031
(-) Working capital	1,187	-4,113	-4,565	-4,358	-4,243	-3,733	-3,256	-2,661
<b>(=) Free cash flows (FCF)</b>	<b>16,105</b>	<b>14,582</b>	<b>18,237</b>	<b>24,506</b>	<b>30,338</b>	<b>37,242</b>	<b>43,750</b>	<b>49,895</b>
<b>PV of FCFs</b>	<b>15,635</b>	<b>12,887</b>	<b>14,673</b>	<b>17,950</b>	<b>20,229</b>	<b>22,607</b>	<b>24,177</b>	<b>25,101</b>

All figures in EUR '000		Terminal EBIT margin							
		11.9%	12.4%	12.9%	13.4%	13.9%	14.4%	14.9%	
PV of FCFs in explicit period	203,139	6.8%	42.23	44.13	46.03	47.93	49.83	51.73	53.62
PV of FCFs in terminal period	316,036	7.8%	34.65	36.09	37.53	38.98	40.42	41.86	43.31
Enterprise value (EV)	519,175	8.8%	29.30	30.43	<b>31.56</b>	<b>32.69</b>	<b>33.82</b>	34.95	36.08
+ Net cash / - net debt	16,133	9.8%	25.32	26.23	<b>27.13</b>	<b>28.04</b>	<b>28.95</b>	29.85	30.76
+ Investments / minority interests	-2,475	10.8%	22.26	22.99	<b>23.73</b>	<b>24.47</b>	<b>25.21</b>	25.95	26.69
Shareholder value	532,833	11.8%	19.83	20.44	21.05	21.66	22.27	22.88	23.49
<b>Fair value per share in EUR</b>	<b>28.00</b>	12.8%	17.85	18.36	18.87	19.38	19.89	20.40	20.91
		Terminal growth rate							
		0.5%	1.0%	1.5%	2.0%	2.5%	3.0%	3.5%	
Cost of equity	10.4%	6.8%	39.33	41.71	44.53	47.93	52.11	57.38	64.23
Pre-tax cost of debt	7.0%	7.8%	33.28	34.90	36.78	38.98	41.59	44.74	48.61
Tax rate	25.0%	8.8%	28.72	29.87	<b>31.19</b>	<b>32.69</b>	<b>34.43</b>	36.46	38.88
After-tax cost of debt	5.3%	9.8%	25.17	26.02	<b>26.97</b>	<b>28.04</b>	<b>29.25</b>	30.65	32.26
Share of equity capital	90.0%	10.8%	22.34	22.98	<b>23.69</b>	<b>24.47</b>	<b>25.35</b>	26.35	27.47
Share of debt capital	10.0%	11.8%	20.04	20.53	21.06	21.66	22.31	23.04	23.86
<b>WACC</b>	<b>9.8%</b>	12.8%	18.13	18.51	18.93	19.38	19.88	20.43	21.04

\*Please note our model runs through 2033 and we have only shown the abbreviated version for formatting purposes

Table 7: CR Energy discounted dividend model

	Unit	2024E	2025E	2026E	2027E	2028E	2029E	TV
<b>EPS</b>	€	<b>3.4</b>	<b>3.9</b>	<b>4.7</b>	<b>5.5</b>	<b>5.9</b>	<b>6.5</b>	<b>7.8</b>
Payout ratio	%	18	15	15	14	15	15	14
Dividend (DPS)	€	0.6	0.6	0.7	0.8	0.9	1.0	1.1
<b>NPV</b>	€	<b>0.6</b>	<b>0.5</b>	<b>0.6</b>	<b>0.6</b>	<b>0.6</b>	<b>0.6</b>	<b>6.6</b>
CAGR 2023 -2028	%	6.3						
Terminal growth rate	%	2.5						
Discount factor	%	9.8						
NPV of dividends	€	5.5						
Terminal value (TV)	€	6.6						
Dividend paid (2023)	€	0.0						
<b>Fair value per share</b>	€	<b>12.00</b>						

\*Our model runs through 2034 and we have only shown the abbreviated version for formatting purposes

Cost of equity	9.8%	After-tax cost of debt	6.4%
Pre-tax cost of debt	6.5%	Share of equity capital	100.0%
Tax rate	2.0%	Share of debt capital	0.0%
<b>WACC</b>	<b>9.8%</b>		



## INCOME STATEMENT

All figures in EUR '000	2019	2020	2021	2022	2023	2024E	2025E
Fair value gains on financial assets	33,747	0	9,185	23,816	27,194	69,997	30,898
Income from participations	780	0	766	207	0	400	400
Investment income	6,651	3,385	3,561	6,605	7,237	10,604	11,405
Other operating income	43	48	35	37	26	27	29
<b>Operating revenue</b>	<b>41,221</b>	<b>3,433</b>	<b>13,547</b>	<b>30,665</b>	<b>34,457</b>	<b>81,028</b>	<b>42,732</b>
SG&A	-934	-841	-923	-987	-1,142	-1,199	-1,259
Other OpEx	-330	-417	-328	-20	0	-20	-21
Net loss from investments	-1,164	-12,453	0	0	-990	0	0
Fair value loss on financial assets	-27,207	-60,720	-21,350	-70	-2,097	-1,500	-1,500
<b>EBITDA</b>	<b>11,586</b>	<b>-70,998</b>	<b>-9,055</b>	<b>29,587</b>	<b>30,228</b>	<b>78,309</b>	<b>39,952</b>
Depreciation & amortisation	-11	-17	-20	-25	-19	-42	-19
<b>EBIT</b>	<b>11,575</b>	<b>-71,015</b>	<b>-9,075</b>	<b>29,562</b>	<b>30,209</b>	<b>78,267</b>	<b>39,933</b>
Interest expense	-540	-510	-194	-169	-576	-300	-300
Interest income	15	75	80	80	135	0	0
<b>EBT</b>	<b>11,050</b>	<b>-71,450</b>	<b>-9,189</b>	<b>29,473</b>	<b>29,768</b>	<b>77,967</b>	<b>39,633</b>
Income taxes	27	1,071	233	-358	-224	-1,559	-793
<b>Net income / loss</b>	<b>11,076</b>	<b>-70,379</b>	<b>-8,956</b>	<b>29,115</b>	<b>29,544</b>	<b>76,408</b>	<b>38,840</b>
<b>EPS (in €)</b>	<b>2.6</b>	<b>-16.4</b>	<b>-2.1</b>	<b>6.8</b>	<b>6.9</b>	<b>17.8</b>	<b>9.1</b>



## BALANCE SHEET

All figures in EUR '000	2019	2020	2021	2022	2023	2024E	2025E
<b>Assets</b>							
<b>Current assets, total</b>	<b>2,237</b>	<b>4,318</b>	<b>4,453</b>	<b>3,960</b>	<b>7,096</b>	<b>7,655</b>	<b>14,476</b>
Cash and equivalents	1,797	369	1,843	1,669	4,552	4,900	11,490
ST financial assets	305	3,865	2,599	2,148	543	554	565
Trade receivables	4	0	0	0	0	0	0
Inventories	0	0	0	0	0	0	0
Other ST assets	131	84	11	143	2,001	2,201	2,421
<b>Non-current assets, total</b>	<b>290,908</b>	<b>206,390</b>	<b>193,543</b>	<b>233,032</b>	<b>259,256</b>	<b>325,260</b>	<b>352,162</b>
Property, plant & equipment	56	43	41	22	8	15	18
Goodwill & other intangibles	1	0	0	0	0	0	0
Financial assets	290,851	206,346	193,502	233,010	259,249	325,246	352,144
<b>Total assets</b>	<b>293,144</b>	<b>210,707</b>	<b>197,996</b>	<b>236,992</b>	<b>266,353</b>	<b>332,915</b>	<b>366,638</b>
<b>Shareholders' equity &amp; debt</b>							
<b>Current liabilities, total</b>	<b>15,724</b>	<b>4,742</b>	<b>4,200</b>	<b>13,740</b>	<b>5,006</b>	<b>289</b>	<b>298</b>
Trade payables	24	36	51	49	54	49	49
Provisions	91	74	101	87	139	143	147
Other ST financial liabilities	15,578	4,613	4,028	12,984	4,721	0	0
Other current liabilities	31	19	20	619	92	97	101
<b>Long-term liabilities, total</b>	<b>5,779</b>	<b>4,703</b>	<b>1,490</b>	<b>1,831</b>	<b>10,380</b>	<b>10,390</b>	<b>10,401</b>
Long-term debt	3,000	3,000	0	0	8,333	8,333	8,333
Deferred tax liabilities & others	2,779	1,703	1,490	1,831	2,047	2,057	2,068
<b>Shareholders' equity</b>	<b>271,641</b>	<b>201,262</b>	<b>192,306</b>	<b>221,421</b>	<b>250,966</b>	<b>322,236</b>	<b>355,939</b>
Minority interests	0	0	0	0	0	0	0
<b>Total equity</b>	<b>271,641</b>	<b>201,262</b>	<b>192,306</b>	<b>221,421</b>	<b>250,966</b>	<b>322,236</b>	<b>355,939</b>
<b>Total consolidated equity and debt</b>	<b>293,144</b>	<b>210,707</b>	<b>197,996</b>	<b>236,992</b>	<b>266,353</b>	<b>332,915</b>	<b>366,638</b>
<b>NAV</b>	<b>271,641</b>	<b>201,262</b>	<b>192,306</b>	<b>221,421</b>	<b>250,966</b>	<b>322,236</b>	<b>355,939</b>
<b>NAVPS (€)</b>	<b>63.5</b>	<b>47.0</b>	<b>44.9</b>	<b>51.7</b>	<b>58.6</b>	<b>75.3</b>	<b>83.1</b>



## CASH FLOW STATEMENT

All figures in EUR '000	2019	2020	2021	2022	2023	2024E	2025E
<b>Net income</b>	<b>11,076</b>	<b>-70,379</b>	<b>-8,956</b>	<b>29,115</b>	<b>29,544</b>	<b>76,408</b>	<b>38,840</b>
Depreciation and amortisation	11	17	20	25	19	42	19
Revaluation gains	-6,540	60,720	12,165	-23,746	-25,097	-68,497	-29,398
Changes in working capital	-93	-3,581	1,619	897	1,027	-197	-212
Other adjustments	384	12,453	-761	-207	989	0	0
Net financial result	526	510	195	170	206	300	300
Tax expense	-26	-1,071	-233	359	224	1,559	793
<b>Operating cash flow</b>	<b>5,337</b>	<b>-1,331</b>	<b>4,049</b>	<b>6,612</b>	<b>6,912</b>	<b>9,615</b>	<b>10,341</b>
Investment income	-6,651	-1,500	-5,173	-6,605	-7,170	-10,604	-11,405
Tax paid	-38	41	38	-3	-1,759	-1,559	-793
<b>Net operating cash flow</b>	<b>-1,352</b>	<b>-2,790</b>	<b>-1,086</b>	<b>4</b>	<b>-2,017</b>	<b>-2,548</b>	<b>-1,856</b>
<b>Cash flow from investing</b>	<b>6,742</b>	<b>12,828</b>	<b>6,366</b>	<b>-8,956</b>	<b>5,405</b>	<b>13,055</b>	<b>13,883</b>
Equity inflow, net	-1	-4	0	0	0	0	0
Debt inflow, net	4,492	-11,000	-12	8,956	8,333	-4,721	0
Dividend paid to shareholders	-8,562	0	0	0	0	-5,138	-5,138
Interest expense	-540	-462	-194	-179	-591	-300	-300
<b>Cash flow from financing</b>	<b>-4,611</b>	<b>-11,466</b>	<b>-206</b>	<b>8,777</b>	<b>7,742</b>	<b>-10,159</b>	<b>-5,438</b>
<b>Liabilities due at beginning of the period</b>	<b>0</b>	<b>0</b>	<b>-3,600</b>	<b>0</b>	<b>-8,247</b>	<b>0</b>	<b>0</b>
<b>Net cash flows</b>	<b>779</b>	<b>-1,428</b>	<b>5,075</b>	<b>-174</b>	<b>2,883</b>	<b>348</b>	<b>6,590</b>
Cash, start of the year	1,018	1,797	369	1,843	1,669	4,552	4,900
<b>Cash, end of the year</b>	<b>1,797</b>	<b>369</b>	<b>1,843</b>	<b>1,669</b>	<b>4,552</b>	<b>4,900</b>	<b>11,490</b>
<b>Free cash flow (FCF)</b>	<b>5,390</b>	<b>10,038</b>	<b>5,280</b>	<b>-8,951</b>	<b>3,388</b>	<b>10,507</b>	<b>12,027</b>
<b>Y-Y Growth</b>							
Operating cash flow	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Free cash flow	-39.1%	86.2%	-47.4%	n.m.	n.m.	210.1%	14.5%



## Imprint / Disclaimer

### First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift:

First Berlin Equity Research GmbH  
Friedrichstr. 34  
10117 Berlin  
Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680

Fax: +49 (0) 30-80 93 9 687

E-Mail: [info@firstberlin.com](mailto:info@firstberlin.com)

Amtsgericht Berlin Charlottenburg HR B 103329 B

UST-Id.: 251601797

Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV

First Berlin Equity Research GmbH

**Authored by: Ellis Acklin, Senior Analyst**

**All publications of the last 12 months were authored by Ellis Acklin.**

**Company responsible for preparation: First Berlin Equity Research GmbH, Friedrichstraße 69, 10117 Berlin**

The production of this recommendation was completed on 8 October 2024 at 11:52

**Person responsible for forwarding or distributing this financial analysis: Martin Bailey**

**Copyright© 2024 First Berlin Equity Research GmbH** No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

### **INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.**

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

### **CONFLICTS OF INTEREST**

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involving a conflict of interests carry on those activities at a level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of MPH Health Care AG the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the MPH Health Care AG for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0.5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;

- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

With regard to the financial analyses of MPH Health Care AG the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the MPH Health Care AG for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

**INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).**

First Berlin notes that it has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

**PRICE TARGET DATES**

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

**AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY**

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

**ASSET VALUATION SYSTEM**

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

**ASSET RECOMMENDATION**

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category		1	2
Current market capitalisation (in €)		0 - 2 billion	> 2 billion
Strong Buy <sup>1</sup>	An expected favourable price trend of:	> 50%	> 30%
Buy	An expected favourable price trend of:	> 25%	> 15%
Add	An expected favourable price trend of:	0% to 25%	0% to 15%
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%
Sell	An expected negative price trend of:	< -15%	< -10%

<sup>1</sup> The expected price trend is in combination with sizable confidence in the quality and forecast security of management.

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of €0 – €2 billion, and Category 2 companies have a market capitalisation of > €2 billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

**RISK ASSESSMENT**

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

**RECOMMENDATION & PRICE TARGET HISTORY**

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	29 October 2012	€24.55	Buy	€55.00
2...29	↓	↓	↓	↓
30	17 January 2023	€15.00	Buy	€56.00
31	8 May 2023	€15.55	Buy	€54.00
32	10 July 2023	€15.30	Buy	€59.00
33	18 October 2023	€14.60	Buy	€62.00
34	13 December 2023	€15.70	Buy	€62.00
35	10 May 2024	€24.80	Buy	€81.00
36	10 June 2024	€33.20	Buy	€81.00
37	12 June 2024	€33.00	Buy	€113.00
38	Today	€23.80	Buy	€108.00

**INVESTMENT HORIZON**

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

### UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

### SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

#### Legally required information regarding

- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: <https://firstberlin.com/disclaimer-english-link/>

**SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main**

### EXCLUSION OF LIABILITY (DISCLAIMER)

#### RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

#### RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

#### INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

#### NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

#### NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

#### DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

#### SEVERABILITY

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

#### APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

#### NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

#### QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

**This report is not intended for distribution in the USA and/or Canada.**